Breaking News Instant updates and real-time market news.

AAPL

Apple

$142.44

1.76 (1.25%)

, SBUX

Starbucks

$60.08

1.04 (1.76%)

07:36
04/21/17
04/21
07:36
04/21/17
07:36

Unusual call flow in option market yesterday

Notable call activity was cited Thursday in Apple (AAPL), Starbucks (SBUX), Comcast (CMCSA), Wal-Mart (WMT), Yelp (YELP), Abercrombie & Fitch (ANF), Skechers (SKX), Foot Locker (FL), Brookdale Senior Living (BKD), and Veeva (VEEV).

AAPL

Apple

$142.44

1.76 (1.25%)

SBUX

Starbucks

$60.08

1.04 (1.76%)

CMCSA

Comcast

$38.00

0.47 (1.25%)

WMT

Wal-Mart

$74.80

0.73 (0.99%)

YELP

Yelp

$33.43

0.6 (1.83%)

ANF

Abercrombie & Fitch

$11.70

0.59 (5.31%)

SKX

Skechers

$26.15

0.24 (0.93%)

FL

Foot Locker

$76.55

3.9 (5.37%)

BKD

Brookdale Senior Living

$13.13

0.06 (0.46%)

VEEV

Veeva

$52.50

1.49 (2.92%)

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 07

    May

  • 24

    May

  • 02

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 20

    Jun

AAPL Apple
$142.44

1.76 (1.25%)

04/20/17
WELS
04/20/17
NO CHANGE
WELS
Market Perform
Apple has 'modest' margin risk from ongoing Qualcomm fight, says Wells Fargo
Wells Fargo analyst Maynard Um noted that Apple (AAPL) has acknowledged it withheld payments to its contract manufacturers in the amount that it felt Qualcomm (QCOM) owed it under a separate cooperation agreement, but that Qualcomm "seems to believe," based on its earnings call comments, that the manufacturers will eventually pay what's contractually owed. With the cooperation agreement having ended at the end of 2016, it remains unclear if Apple will have to pay its contract manufacturers the cited $1B over three quarters, which leaves "modest risk" on the possibility for an increase in cost of goods and associated hit to gross margins, said Um, who has a Market Perform rating on Apple shares.
04/20/17
UBSW
04/20/17
NO CHANGE
Target $58
UBSW
Neutral
Qualcomm guidance not as bad as feared, says UBS
UBS analyst Stephen Chin noted Qualcomm (QCOM) reported a strong Q2 beat but he maintained his Neutral rating due to uncertainty over future Apple (AAPL) payments as its lawsuit remains unresolved and it disclosed there is a new underpaying licensee. Chin said fundamentals remain mixed near-term, but added that the company's guidance was not as bad as feared. Chin has a $58 price target on Qualcomm shares.
04/20/17
STFL
04/20/17
NO CHANGE
STFL
Apple price target raised to $150 from $130 at Stifel
Stifel analyst Aaron Rakers continues to expect Apple to report in-line Q2 results. However, he raised his 2017 and 2018 estimates for the company ,citing historical data on the percent of the iPhone installed base that bought the newest iPhones and the ratio of new iPhones shipped to total iPhone sales. However, Rakers keeps a Hold rating on the stock.
04/21/17
OPCO
04/21/17
NO CHANGE
OPCO
Perform
Verizon responding to wireless competition, says Oppenheimer
Oppenheimer analyst Timothy Horan expects Verizon's (VZ) equipment revenue in Q4 to be strong, linked to the release of the new iconic Apple (AAPL) iPhone 8. The analyst believes wireless competition will remain elevated, but Verizon is responding, and will remained focused on network quality. Further, Horan says Verizon is integrating Yahoo (YHOO)/AOL to deliver growth from programmatic ads/digital content, but this will take some time. He reiterates a Perform rating on Verizon's shares.
SBUX Starbucks
$60.08

1.04 (1.76%)

04/20/17
04/20/17
UPGRADE

Buy
Starbucks upgraded to Buy on valuation at Stifel
As previously reported, Stifel upgraded Starbucks to Buy from Hold and raised its price target to $67 from $60. Analyst Mark Astrachan views valuation as attractive and expects multiple expansion from accelerating US comp store sales growth to at least 5%-6% for the next four quarters starting in the June quarter. The analyst said shares have underperformed consumer and restaurant peers over the past 12 months and expects outperformance to be driven by meeting comp expectations.
04/04/17
MAXM
04/04/17
NO CHANGE
Target $260
MAXM
Hold
Sale of Panera Bread looks unlikely, says Maxim
A potential sale of Panera Bread (PNRA) looks "unlikely," Maxim Group's Stephen Anderson said in a pre-market research note. Media reports named Starbucks (SBUX) and Domino's Pizza (DPZ) as possible suitors, and he adds McDonald's (MCD), Yum! Brands (YUM) and Restaurant Brands (QSR) to the list of hypothetical buyers, with Starbucks potentially emerging as the most likely partner. Anderson cautions that, given the recent CEO transition at Starbucks as well as its desire to focus on premium coffee, he would still consider a tie-up between the coffee giant and Panera as unlikely. Moreover, a sale would probably come at just a "modest" premium to recent levels, with Anderson estimating a $295-$310 takeout price. The analyst reiterates his Hold rating and $260 price target on Panera shares.
04/20/17
04/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Starbucks (SBUX) upgraded to Buy from Hold at Stifel with analyst Mark Astrachan saying he views valuation as attractive and expects multiple expansion from accelerating U.S. comparable store sales growth to at least 5%-6% for the next four quarters starting in the June quarter. The analyst said shares have underperformed consumer and restaurant peers over the past 12 months and expects outperformance to be driven by meeting comp expectations. 2. Goldman Sachs (GS) upgraded to Overweight from Neutral at Atlantic Equities with analyst Christopher Wheeler telling investors investors shares are "oversold." The analyst expects the FICC business to bounce back and made just a small reduction in estimates to account for further cost measures. 3. Lear (LEA) upgraded to Outperform from Neutral at Baird with analyst David Leiker citing its recent underperformance despite improving fundamentals and a strong global auto backdrop. Leiker raised his price target to $161 from $160 on Lear shares. 4. Discovery (DISCA) upgraded to Neutral from Sell at Citi with analyst Jason Bazinet saying he sees little chance of material downward revisions to consensus earnings estimates. The analyst views the risk/reward as more balanced at current levels and upped his price target for the shares to $30 from $27. 5. Gap (GPS) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss citing the underperformance of the shares over the past 18 months and his fieldwork which suggests stability at Old Navy. The analyst raised his price target for the shares to $24 from $21. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/19/17
STFL
04/19/17
UPGRADE
STFL
Buy
Starbucks upgraded to Buy from Hold at Stifel
CMCSA Comcast
$38.00

0.47 (1.25%)

04/20/17
WELS
04/20/17
NO CHANGE
WELS
Comcast shares attractive into Q1 results, says Wells Fargo
Wells Fargo says that Comcast's stock is very attractive ahead of its Q1 results. The firm increased its Q1 cable network and film estimates for the company, and raised its overall Q1 estimates above consensus levels. It keeps an Outperform rating on the shares.
04/20/17
BTIG
04/20/17
NO CHANGE
BTIG
Comcast should try 'hail mary' Charter acquisition, says BTIG
BTIG analyst Rich Greenfield makes the case that Comcast's (CMCSA) "window for M&A is simply to enticing too ignore" and lays out six potential targets that would "truly be transformative," with his top pick among the group being Charter (CHTR). A combination of Charter with Comcast would have "all of the benefits of the legacy Time Warner Cable deal with even more scale" and even though odds of approval are no better than 50/50, it is worth throwing that "hail-mary," Greenfield tells investors. The other five possible deals that Greenfield makes the case for are Disney (DIS), Verizon (VZ), Netflix (NFLX), T-Mobile (TMUS) and Snap Inc.'s (SNAP) Snapchat.
04/18/17
RHCO
04/18/17
INITIATION
Target $45
RHCO
Buy
Comcast initiated with a Buy at SunTrust
SunTrust analyst Greg Miller started Comcast with a Buy rating and $45 price target. The analyst prefers cable names over wireless given a "more supportable growth outlook and greater potential to preserve margins."
04/17/17
JPMS
04/17/17
NO CHANGE
JPMS
Overweight
JPMorgan not reading into TiVo, Comcast ITC ruling change
JPMorgan analyst Sterling Auty does not believe there is anything to read into from the International Trade Commission preliminary judgment in the TiVo (TIVO), Comcast (CMCSA) case being pushed out from the end of April to the end of May. This is likely procedural now that the ITC has finished another case and can focus its attention on TiVo/Comcast, Auty tells investors in a research note. He keeps an Overweight rating on TiVo.
WMT Wal-Mart
$74.80

0.73 (0.99%)

04/18/17
KEYB
04/18/17
NO CHANGE
KEYB
Wal-Mart outlook has improved, says KeyBanc
KeyBanc is more confident in Wal-Mart's near-term and long-term momentum after examining credit card data and visiting one of the company's latest Supercenter prototypes. The firm says that the credit card data indicates that the company's store traffic accelerated by 1.6 percentage points in March. The firm believes that the prototype suggests that the company is going to use technology more effectively to improve customers' experience and lower costs. KeyBanc expects Wal-Mart's Q1 EPS and SSS to beat expectations. It keeps a $90 price target and an Overweight rating on the shares.
04/10/17
MSCO
04/10/17
DOWNGRADE
MSCO
Underweight
J.M. Smucker downgraded on Wall-Mart, private label risk at Morgan Stanley
As previously reported, Morgan Stanley downgraded J.M. Smucker (SJM) to Underweight from Equal Weight saying increased retail competition adds to a challenging US Foods backdrop. Analyst Matthew Grainger sees two headwinds emerging from Wal-Mart's (WMT) increased leverage over Food manufacturers and renewed private label growth. The analyst said Wal-Mart's total grocery sales have grown at a fast 4% CAGR, giving increased leverage over Food manufacturers, and private label trends have inflected across a range of center-store categories, which could intensify an already competitive retail grocery landscape. Grainger said J.M. Smucker's has outsized risk to Wal-Mart and private label risk , and as a result downgraded shares and lowered his price target to $126 from $132.
04/19/17
WEDB
04/19/17
NO CHANGE
WEDB
Outperform
Wayfair among 'most ripe' online pure-play takeover targets, says Wedbush
Wedbush analyst Seth Basham says Wal-Mart (WMT) may have started a trend of major online pure play acquisitions with its acquisition of Jet.com last year, pointing to PetSmart's "pricey" acquisition of online retailer Chewy.com yesterday as an extension of that trend. Within this backdrop, traditional retailers, and investors, may be recognizing online pure plays are tough to beat and may be best viewed as targets, contends Basham, who calls Wayfair (W) "one of the most ripe acquisition targets" in the space. The analyst, who lays out a large number of potential suitors for Wayfair, has an Outperform rating on the shares.
04/20/17
WOLF
04/20/17
DOWNGRADE
WOLF
Peer Perform
Amazon downgraded by Wolfe Research with 'retail bloodbath' seen ahead
As previously reported, Wolfe Research downgraded Amazon.com to Peer Perform from Outperform. Analyst Scott Mushkin said shares are approaching his price target and he expects increasing competition through year-end. He expects next year to be a "bloodbath" in retail due to increased competition from Wal-Mart (WMT), traditional consumable operators, and other broadlines/specialty retailers, leading to a deceleration in Amazon sales, he tells investors. Mushkin reduced his FY17 earnings estimate to $6.52 from $6.63 and FY18 to $9.92 from $10.09 due mostly to lowered expectations in North America.
YELP Yelp
$33.43

0.6 (1.83%)

04/11/17
04/11/17
UPGRADE
Target $43

Overweight
Yelp upgraded to Overweight on 'underappreciated core' at Pacific Crest
As previously reported, Pacific Crest analyst Brad Erickson upgraded Yelp (YELP) to Overweight from Sector Weight, saying his checks with local ad customers indicate Yelp's core franchise is healthy and appears insulated from larger competitors like Google (GOOG) and Facebook (FB). Over $60B of offline local ad spending is shifting toward online and Yelp remains well-positioned to capitalize on this trend, though its core business is underappreciated in the shares' current value, said Erickson, who has a $43 price target on the stock.
04/11/17
PACS
04/11/17
UPGRADE
Target $43
PACS
Overweight
Yelp upgraded to Overweight from Sector Weight at Pacific Crest
Pacific Crest analyst Brad Erickson upgraded Yelp to Overweight with a $43 price target.
04/11/17
04/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Conviction Buy from Buy at Goldman with analyst Drew Borst saying that the success of "Beauty and the Beast" has increased his confidence in his forecast that FY18 EPS growth will accelerate given the company's promising film slate and its read-through to consumer products. He also sees accelerating profit growth at ESPN given normalizing NBA costs and predicts record results for the Theme Parks segment. Borst keeps a $138 price target on Disney shares. 2. McDonald's (MCD) upgraded to Buy from Neutral at Cleveland Research. 3. Yelp (YELP) upgraded to Overweight from Sector Weight at Pacific Crest with analyst Brad Erickson saying his checks with local ad customers indicate Yelp's core franchise is healthy and appears insulated from larger competitors like Google (GOOG, GOOGL) and Facebook (FB). 4. Toll Brothers (TOL) upgraded to Outperform from Sector Perform at RBC Capital with analyst Robert Wetenhall citing "solid demand,strong execution, proven management, a strong luxury housing business, and consistent earnings." 5. Sanofi (SNY) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he no longer sees downside to consensus estimates. The pressure on the diabetes business now seems largely reflected in estimates, Vosser tells investors in a research note. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/13/17
DBAB
04/13/17
NO CHANGE
Target $52
DBAB
Buy
Negative sentiment on Yelp overblown, says Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley said negative sentiment on Yelp has been overblown and he expects Local Advertising Account additions to perform better in Q1. Improving self-serve infrastructure can drive higher ARPU and allow the company room to spend more on marketing, added Walmsley, who sees "the bar here as low for Yelp" ahead of the company's upcoming earnings report. He keeps a Buy rating and $52 price target on Yelp shares.
ANF Abercrombie & Fitch
$11.70

0.59 (5.31%)

01/03/17
01/03/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Jefferies analyst Randal Konik downgraded Abercrombie & Fitch (ANF) to Hold saying the turnaround continues to struggle at the Abercrombie brand, with no visibility of a turnaround in sight. Also this morning, Oppenheimer analyst Anna Andreeva downgraded Abercrombie & Fitch to Underperform, saying consensus estimates have further downside as the brands "remain in transition amidst increasingly more competitive teen landscape." 2. Oppenheimer analyst Ittai Kidron downgraded Tableau (DATA) to Perform from Outperform to reflect the scope of near-term transition challenges integrating new leadership, the ratable shift, and competition, all hampering near-term upside potential. The analyst also cut Nokia's (NOK) rating to Perform from Outperform. 3. Piper Jaffray analyst Erinn Murphy downgraded Michael Kors (KORS) to Neutral saying the handbag category has been "highly promotional" while inventory levels have been high, particularly at department stores. The analyst sees no positive catalyst in the near-term for shares to re-rate higher and cut her price target for Kors to $48 from $60. 4. JPMorgan analyst Jimmy Bhullar downgraded Voya Financial (VOYA) to Underweight saying the risk/reward skews negative following the stock's outperformance in the second half of 2016. The analyst remains concerned about Voya's "subpar" return-on-equity. 5. JPMorgan analyst Michael Weinstein downgraded Medtronic (MDT) to Neutral saying the new macro environment of rising rates and a strengthening dollar will make it challenging for the shares to outperform in 2017. This morning Weinstein also downgraded Becton Dickinson (BDX) to Neutral saying the new macro environment of rising rates and a strengthening dollar will make it challenging for defensive growth names to outperform in 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/03/17
WOLF
03/03/17
DOWNGRADE
WOLF
Underperform
Abercrombie & Fitch downgraded to Underperform at Wolfe Research
Wolfe Research downgraded Abercrombie & Fitch to Underperform from Peer Perform with a $10 price target citing low visibility into a comp turnaround, margin contraction, and a potentially unsustainable dividend yield.
01/04/17
FBRC
01/04/17
UPGRADE
Target $13
FBRC
Market Perform
FBR upgrades Abercrombie to Market Perform after selloff
FBR Capital analyst Susan Anderson upgraded Abercrombie & Fitch to Market Perform from Underperform citing the stock's 28% decline since her November 15, 2016 downgrade. Near-term negative results are likely priced into the stock, Anderson tells investors in a research note. She believes, however, that Abercrombie's same-store-sales will remain challenged driven by the A&F brand and Europe. The analyst lowered her price target for the shares to $13 from $14.
01/04/17
FBRC
01/04/17
UPGRADE
Target $13
FBRC
Market Perform
Abercrombie & Fitch upgraded to Market Perform from Underperform at FBR Capital
FBR Capital analyst Susan Anderson upgraded Abercrombie & Fitch to Market Perform with a slightly reduced price target of $13.
SKX Skechers
$26.15

0.24 (0.93%)

04/10/17
04/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Overweight from Neutral at Piper Jaffray analyst Alexander Potter saying while Model 3 production headlines could create stock volatility, growth investors "can't afford to ignore this stock." Tesla's products have a "captivating impact on consumers and shareholders alike," an advantage that will be hard to replicate, the analyst adds. Potter is more convinced following meetings with management that Model 3 deliveries will begin in 2017. The analyst raised his price target for the shares to $368 from $223. 2. Amazon.com (AMZN) upgraded to Buy from Hold at Needham with analyst Kerry Rice saying he believes its established dominance in U.S. is sustainable with Prime, mobile penetration and third-party growth. Internationally, the analyst believes Europe provides the most near-term upside, while he views India as one of "the most exciting" long-term opportunities. Rice also believes AWS should continue to be a key driver for the company's bottom line growth. 3. Wells Fargo (WFC) upgraded to Neutral from Underweight at Piper Jaffray with analyst Kevin Barker saying headwinds from the account scandal are now embedded in consensus estimates and the stock's valuation. The analyst raised his price target for the shares to $55 from $52. 4. Ulta Beauty (ULTA) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying Ulta is the most compelling fundamental story in retail today. Chukumba feels the struggles of high-end department stores plays right into the company's hands. He also thinks Ulta is overdue for a stock split. 5. Skechers (SKX) upgraded to Neutral from Negative at Susquehanna with analyst Sam Poser saying shares are fairly valued and reflect near-term challenges following recent share weakness. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/17
SUSQ
04/10/17
UPGRADE
SUSQ
Neutral
Skechers upgraded to Neutral from Negative at Susquehanna
Susquehanna analyst Sam Poser upgraded Skechers to Neutral with a $25 price target saying shares are fairly valued and reflect near-term challenges following recent share weakness.
04/21/17
RILY
04/21/17
UPGRADE
Target $32
RILY
Buy
Skechers upgraded to Buy from Neutral at B. Riley
B. Riley analyst Jeff Van Sinderen upgraded Skechers to Buy citing "strong" international growth and worldwide comps following the company's better than expected Q1 results. The analyst raised his price target for the shares to $32 from $28.
03/24/17
03/24/17
UPGRADE
Target $35

Outperform
Skechers upgraded to Outperform on international mix shift at Cowen
As previously reported, Cowen upgraded Skechers to Outperform from Market Perform and raised its price target to $35 from $26. Analyst John Kernan said Skechers mix shift to an international wholesale-driven model, led by distributor-owned and franchise stores, will produce margin expansion and accelerate earnings and free cash flow growth. Kernan believes Skechers' valuation looks attractive given above average sector sales and +10% earnings CAGR though 2019, improving ROIC, and potential for $1B cash on the balance sheet.
FL Foot Locker
$76.55

3.9 (5.37%)

04/20/17
BUCK
04/20/17
UPGRADE
BUCK
Buy
Foot Locker upgraded to Buy from Neutral at Buckingham
02/27/17
COWN
02/27/17
NO CHANGE
Target $77
COWN
Outperform
Foot Locker one of healthiest brands in retail, says Cowen
Cowen analyst John Kiernan called Foot Locker one of the healthiest brands in retail following it Q4 results. The analyst cited the company's growth in traffic, average selling prices, and margins. Kiernan reiterated his Outperform rating and raised his target to $77 from $74 on Foot Locker shares.
02/27/17
ADAM
02/27/17
NO CHANGE
Target $87
ADAM
Buy
Foot Locker reiterated as a top pick for 2017 at Canaccord
Canaccord analyst Camilo Lyon noted Foot Locker reported solid Q4 results and bucked the trend of a challenging retail environment. Lyon cited the company's ability to drive positive store traffic, its ability to execute with consistency, and its stock buyback program. Lyon maintained his Buy rating and raised his price target to $87 from $83 on Foot Locker shares.
04/20/17
04/20/17
UPGRADE

Buy
Update: Foot Locker upgraded on accelerating trends at Buckingham
As previously reported, Buckingham upgraded Foot Locker to Buy from Neutral and raised its price target to $89 from $77 based on expectations for an acceleration in same-store-sales trends, expanding merchandise margins, and increased share buybacks. The firm believes the major long-term bear thesis on Footlocker that customers move to Nike.com is more muted with other athletic brands gaining share and said the company has a sustainable and defensible concept that resonates with customers.
BKD Brookdale Senior Living
$13.13

0.06 (0.46%)

01/12/17
WELS
01/12/17
UPGRADE
WELS
Outperform
Brookdale upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Ryan Halsted upgraded Brookdale Senior Living (BKD) to Outperform citing a higher probability that the company will sell some or all of its assets. The analyst raised his price target range for the shares to $18-$21 from $14-$16. A sale of the whole company to Blackstone (BX) is a possibility, Halsted tells investors in a research note.
02/17/17
STFL
02/17/17
NO CHANGE
STFL
Acquisition of Brookdale Senior Living 'could make sense,' says Stifel
After Dow Jones reported that Ventas (VTR) is in talks to acquire all or part of Brookdale Senior Living (BKD), Stifel analyst Chad Vanacore says the report "could have merit," although "there are hurdles." The analyst says the deal "could make sense," since Veritas "is acquisitive." However, the analyst says that other REITs from whom Brookdale leases properties would have to agree to a deal, creating hurdles. He continues to believe that Brookdale's valuation is attractive and that it can benefit from a real estate value unlocking transaction. Vanacore keeps a Buy rating on the stock.
03/27/17
JEFF
03/27/17
UPGRADE
Target $16.5
JEFF
Buy
Brookdale Senior Living upgraded to Buy from Hold at Jefferies
Jefferies analyst Brian Tanquilut upgraded Brookdale Senior Living to Buy citing an improved risk/reward following the recent pullback in the shares. The analyst sees a greater than 50% probability that Brookdale's ongoing sale process results in a deal, but thinks the stock can reach $14.50 even without a takeout. He upped his price target for the shares to $16.50 from $14.
03/27/17
03/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Adobe (ADBE) upgraded to Buy from Neutral at BTIG. 2. Best Buy (BBY) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying store closures from hhgregg and potentially Sears (SHLD) could lift Best Buy's comp sales by 2%, Keith tells investors in a research note. Further, the upcoming iPhone and Samsung Galaxy Note launches should bring a "strong smartphone upgrade cycle," the analyst contends. 3. HCA Holdings (HCA) and Universal Health (UHS) were upgraded to Buy from Neutral at Mizuho. 4. Weatherford (WFT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Judson Bailey citing greater confidence in improving operations with the hire of CEO Mark McCollum and the formation of the OneStim joint venture. 5. Brookdale Senior Living (BKD) upgraded to Buy from Hold at Jefferies with analyst Brian Tanquilut citing an improved risk/reward following the recent pullback in the shares. The analyst sees a greater than 50% probability that Brookdale's ongoing sale process results in a deal, but thinks the stock can reach $14.50 even without a takeout. He upped his price target for the shares to $16.50 from $14. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VEEV Veeva
$52.50

1.49 (2.92%)

03/01/17
MSCO
03/01/17
NO CHANGE
Target $53
MSCO
Overweight
Veeva has a long runway of growth, says Morgan Stanley
Morgan Stanley analyst Stan Zlotsky said Veeva reported an impressive quarter and outlook and continues to view the company as a rare asset in software, combinign growth, leverage,a nd an expanding TAM story. The analyst does not believe Veeva's optionality outside of life sciences is reflected in valuation and said the company has a long runway for growth going forward. Zlotsky rates Veeva an Overweight with a $53 price target.
01/12/17
EVER
01/12/17
DOWNGRADE
Target $47
EVER
Hold
Veeva downgraded to Hold from Buy at Evercore ISI
Evercore ISI analyst Kirk Materne downgraded Veeva to Hold citing balanced risk/reward after rallying 41% in 2016 and maintained its $47 price target.
01/25/17
STFL
01/25/17
NO CHANGE
STFL
Stifel lists potential takeout candidates following AppDynamics deal
Cisco's (CSCO) acquisition of AppDynamics (APPD) is a sign that the wave of Software deal activity in 2016 has carried over into the new year, Stifel analyst Brad Reback tells investors in a research note. He believes the deal bodes well for the small- and mid-cap names across his firm's coverage list, including potential consolidation candidates such as Barracuda (CUDA), ChannelAdvisor (ECOM), FireEye (FEYE), HubSpot (HUBS), Paycom (PAYC), Paylocity (PCTY), Proofpoint (PFPT), SecureWorks (SCWX), Splunk (SPLK), Tableau (DATA), Ultimate Software (ULTI), Veeva (VEEV) and Zendesk (ZEN). He notes that AppDynamics most directly competes against other application performance management vendors such as New Relic (NEWR and privately-held Dynatrace.
03/29/17
WEDB
03/29/17
NO CHANGE
Target $43
WEDB
Neutral
Wedbush does not see Oracle moving forward with Accenture
Wedbush analyst Steve Koenig says he's skeptical that The Register's report of Oracle (ORCL) performing due diligence on a potential acquisition of Accenture (ACN) will progress very far. Look beyond Accenture for potential acquisition targets, Koenig tells investors in a research note. The analyst thinks more interesting targets lie elsewhere, including vendors such as health care specialists athenahealth (ATHN) and Veeva Systems (VEEV). He reiterates a Neutral rating on Oracle with a $43 price target.

TODAY'S FREE FLY STORIES

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.